Huston Robert K, Christensen J Mark, Karnpracha Chanida, Rosa Jill E, Clark Sara M, Migaki Evelyn A, Wu YingXing
Northwest Newborn Specialists, PC and Pediatrix Medical Group, Portland, OR, United States of America.
Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Corvallis, OR, United States of America.
PLoS One. 2014 Sep 5;9(9):e106825. doi: 10.1371/journal.pone.0106825. eCollection 2014.
We have previously reported results of precipitation studies for neonatal parenteral nutrition solutions containing calcium chloride and sodium phosphate using visual methods to determine compatibility. The purpose of this study was to do further testing of compatibility for solutions containing calcium chloride using more sensitive methods.
Solutions of Trophamine (Braun Medical Inc, Irvine, CA) and Premasol (Baxter Pharmaceuticals, Deerfield, IL) were compounded with calcium chloride and potassium phosphate. Controls contained no calcium or phosphate. After incubation at 37° for 24 hours solutions without visual precipitation were analyzed to determine mean particle size using dynamic light scattering from a laser light source.
Particle sizes were similar for control solutions and those without visual precipitation and a mean particle size <1000 nm. Compatible solutions were defined as those with added calcium and phosphate with no visual evidence of precipitation and mean particle size <1000 nm. In solutions containing 2.5-3% amino acids and 10 mmol/L of calcium chloride the maximum amount of potassium phosphate that was compatible was 7.5 mmol/L.
Maximum amounts of phosphate that could be added to parenteral nutrition solutions containing Trophamine and calcium chloride were about 7.5-10 mmol/L less for a given concentration of calcium based upon laser methodology compared to visual techniques to determine compatibility. There were minor differences in compatibility when adding calcium chloride and potassium phosphate to Premasol versus Trophamine.
我们之前报告了使用视觉方法测定含氯化钙和磷酸钠的新生儿肠外营养溶液的沉淀研究结果。本研究的目的是使用更灵敏的方法对含氯化钙的溶液进行进一步的相容性测试。
将特罗法明(布劳恩医疗公司,加利福尼亚州欧文市)和普雷马索尔(百特制药公司,伊利诺伊州迪尔菲尔德市)溶液与氯化钙和磷酸钾混合。对照组不含钙或磷。在37℃孵育24小时后,对无肉眼可见沉淀的溶液进行分析,使用激光光源的动态光散射测定平均粒径。
对照组对于对照溶液和无肉眼可见沉淀的溶液,粒径相似,平均粒径<1000nm。相容性溶液定义为添加了钙和磷且无肉眼可见沉淀迹象且平均粒径<1000nm的溶液。在含有2.5 - 3%氨基酸和10mmol/L氯化钙的溶液中,与之相容的磷酸钾的最大量为7.5mmol/L。
与视觉技术相比,基于激光方法测定相容性时,对于给定浓度的钙,添加到含特罗法明和氯化钙的肠外营养溶液中的磷酸盐最大量约少7.5 - 10mmol/L。在向普雷马索尔中添加氯化钙和磷酸钾与向特罗法明中添加时,相容性存在细微差异。